In Q2, 2018 ISR surveyed 100 outsourcers of bioprocessing / biologic API manufacturing to learn what they predict their company’s biologics portfolio will look like five years from now. On average, respondents anticipate monoclonal antibodies will account for one-third of their company’s biologics portfolio. Cell therapies followed at a distance for second position, averaging at 13 percent of the aggregated biologics portfolio. To learn more, follow the link to the Bioprocessing Market Trends and Outsourcing Dynamics: 2018-2023 (2nd Edition) report preview.   Originally published at Bioprocess Online.   View File